US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

CMS News | HHS | USA | Medicare, and Medicaid | Health insurance | Healthcare News

2022 FDA Drug Approvals

COVID19 drug updates | FDA EMA approved COVID19 drugs

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief

FDA approved Novartis Scembli for chronic myeloid leukemia

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

CMS News | US Healthcare News | Medicare and Medicaid News |

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

Gilead’s Trodelvy approved for triple-negative breast cancer in US

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

US FDA approved BMS gene therapy Breyanzi

Merck and Bayer announced the US FDA approval for Verquvo

Expected best selling pharmaceutical products (drugs) in 2021

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

CMS News

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Novartis Kesimpta approved for relapsing multiple sclerosis in the US

FDA says no to Gilead’s most anticipated product filgotinib

Genentech’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder in the US

US FDA approved another drug for rare Duchenne Muscular Dystrophy

Gilead submitted NDA for Veklury to treat COVID-19 in the US

FDA approved Genentech’s Evrysdi for Spinal Muscular Atrophy

NOVARTIS COSENTYX APPROVED IN EUROPE FOR PAEDIATRIC PSORIASIS

GSK’s first anti-BCMA therapy Blenrep was approved in the US